Showing 1 - 10 of 43,525
Background In their interesting systematic review, Gallehzan et al. quoted our article Cost-utility analysis of teriflunomide in naïve vs. previously treated patients with relapsing-remitting multiple sclerosis (RRMS) in Italy. While we are grateful to Gallehzan et al. for their interest in the...
Persistent link: https://www.econbiz.de/10015371820
Persistent link: https://www.econbiz.de/10012299513
Persistent link: https://www.econbiz.de/10012586516
Persistent link: https://www.econbiz.de/10012221328
Persistent link: https://www.econbiz.de/10012221637
Persistent link: https://www.econbiz.de/10014327973
Persistent link: https://www.econbiz.de/10011868215
Persistent link: https://www.econbiz.de/10014476102
Persistent link: https://www.econbiz.de/10014529772
Persistent link: https://www.econbiz.de/10013279206